A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Summary
Third Opinion Trial Synopsis:
This study wants to see if a certain group of medicines called CyBorD with daratumumab SC is safe and helpful for people with kidney disease caused by something called MGRS. The researchers also want to know if this medicine can treat a specific kind of kidney disease that happens with a type of cancer called multiple myeloma.
This study wants to see if a certain group of medicines called CyBorD with daratumumab SC is safe and helpful for people with kidney disease caused by something called MGRS. The researchers also want to know if this medicine can treat a specific kind of kidney disease that happens with a type of cancer called multiple myeloma.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: